Forensic Investigation Goes Mobile With Thales
For decades, Thales expertise has allowed investigation professionals to record, analyze and compare biometric characteristics with the highest level of performance. Today, Thales puts forensic investigations to the next level with one of the top NIST -ranked solutions, uncompromised on accuracy, customizability, and scalability. With its new Evidence & Investigation Suite, Thales put the emphasis on remote accessibility and utmost mobility, offering forces full flexibility and improved results.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230821357652/en/
According to the World Bank, 7 out of 10 individuals will live in cities by 20501. This rise in global urbanization leads to a significant need for technology to effectively improve public security. Thales Evidence and Investigation Suite is a cloud-based comprehensive suite of solutions and services that fulfill security forces' time constraints and flexibility demands. The Suite boosts and enhances the current capabilities of field operations by allowing investigators to access highly professional tools remotely on their mobile phones from anywhere.
“In the fight against crime, time is the enemy”, highlights Luc Tombal, Public Security Solutions Director at Thales “ that’s why Thales Evidence & Investigation Suite was created by experts with extensive field knowledge for experts.”
Thales’ solution comprises compact devices that can capture biometric data such as facial and iris images, finger- and palmprints wherever they are needed; as well as secure data storage capacity and processing tools that support forensic teams during investigations. The security forces can rely on Thales and its 30+ years of biometrics expertise when making critical decisions in the fight against crime.
“Thanks to the ultra-mobile multifunction application, each investigator can benefit from having a biometric forensic lab at the palm of their hand that strives to simplify and accelerate the procedure. Time optimization is crucial in investigations, and this unique approach allows access to vital information within minutes, expediting criminal case resolutions compared to the traditional days-long process,” added Luc Tombal.
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.
Thales has 77,000 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Thales, Media Relations
Digital Identity and Security
+33 (0)6 07 34 00 34
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Provides Update on EXKIVITY® (mobocertinib)2.10.2023 23:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that, following discussions with the U.S. Food and Drug Administration (FDA), it will be working with the FDA towards a voluntary withdrawal of EXKIVITY ® (mobocertinib) in the U.S. for adult patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on or after platinum-based chemotherapy. Takeda intends to similarly initiate voluntary withdrawal globally where EXKIVITY is approved and is working with regulators in other countries where it is currently available on next steps. This decision was based on the outcome of the Phase 3 EXCLAIM-2 confirmatory trial, which did not meet its primary endpoint and thus did not fulfill the confirmatory data requirements of the Accelerated Approval granted by the U.S. FDA nor the conditional marketing approvals granted in other countries. The EXCLAIM-2 trial was a Phase
Galderma announces progress with RelabotulinumtoxinA regulatory submissions2.10.2023 23:27:00 EEST | Press release
Galderma, the emerging pure-play dermatology category leader, announced today updates related to the regulatory progress of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA (QM-1114) to the U.S. Food and Drug Administration (“FDA”). The FDA has issued a Complete Response Letter (“CRL”) to Galderma related to its BLA for RelabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines (frown lines) associated with corrugator and/or procerus muscle activity in adult patients as well as moderate-to-severe lateral canthal lines (crow’s feet) associated with orbicularis oculi muscle activity in adult patients. The CRL points out certain deficiencies isolated to items related to Chemistry, Manufacturing, and Controls (“CMC”) processes. All other aspects of the BLA, including safety and efficacy related parts, did not solicit deficiencies to be addressed. Galderma has already identified changes to the manufacturing process to address feedback. It will also
Visa Launches $100 million Generative AI Ventures Initiative2.10.2023 23:05:00 EEST | Press release
Visa (NYSE: V), a global leader in payments, today announced a new $100 million generative AI ventures initiative to invest in the next generation of companies focused on developing generative AI technologies and applications that will impact the future of commerce and payments. As a pioneer of AI use in payments since 1993, Visa considers this initiative an extension of Visa’s leadership in using AI to drive innovation in payments, create value for partners and clients, and enable and empower global commerce. Generative AI is an emerging subset of AI that is built on Large Language Models (LLMs) to develop artificial general intelligence capable of generating text, images or other content from large sets of existing data when given prompts. “While much of generative AI so far has been focused on tasks and content creation, this technology will soon not only reshape how we live and work, but it will also meaningfully change commerce in ways we need to understand,” said Jack Forestell,
MSCI Completes Acquisition of Burgiss2.10.2023 23:05:00 EEST | Press release
MSCI Inc. (NYSE: MSCI), a leading provider of mission-critical decision support tools and services for the global investment community, today announced that it has completed its acquisition of The Burgiss Group, LLC (“Burgiss”), a market-leading provider of data, analytics, and technology solutions for investors in private assets. The acquisition was originally announced on August 14, 2023. Henry Fernandez, Chairman and Chief Executive Officer, MSCI, said: “We are thrilled to complete this acquisition. By making Burgiss part of our integrated franchise, MSCI will dramatically expand and strengthen our solutions across client segments. In the process, we will help promote greater transparency for investors in private assets." About MSCI Inc. MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data, and technology, we power better investment decisions by enabling clients to understand
Carbios Unveils Major Innovation in Polyester Recycling With New Textile Preparation Line, in the Presence of Roland Lescure, French Minister of Industry2.10.2023 19:00:00 EEST | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231002227008/en/ Roland Lescure, French Minister of Industry (left) accompanied by Emmanuel Ladent, CEO Carbios (far right) and representatives of Carbios partner brands (On, Salomon and Puma), inaugurates the textile preparation line for biorecycling. (Photo: Carbios) Carbios, (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, today inaugurated its textile preparation line at its demonstration plant in Clermont-Ferrand, in the presence of Mr. Lescure, French Minister for Industry. To streamline the textile preparation phase, which is currently carried out by hand or on several lines, Carbios has developed a fully integrated and automated line that transforms textile waste from used garments or cutting scraps into raw material suitable for depolymerizat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom